1.01

2.88% -0.03

After Hours: 1.01

MiNK Therapeutics Inc (INKT)

Overview News Price History Financials Discussions Forecast

MiNK Therapeutics Inc stock is currently priced at $1.01, with a 24-hour trading volume of 68,762. It has seen a -2.88% decreased in the last 24 hours and a +10.35% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.04 pivot point. If it approaches the $0.98 support level, significant changes may occur.

Previous Close:

$1.04

Open:

$1.02

24h Volume:

68,762

Market Cap:

$35.07M

Revenue:

Net Income/Loss:

$-24.77M

P/E Ratio:

-1.3117

EPS:

-0.77

Net Cash Flow:

$-17.36M

1W Performance:

+12.22%

1M Performance:

+10.35%

6M Performance:

-1.94%

1Y Performance:

-43.89%

1D Range:

$0.98

$1.0399

52W Range:

$0.75

$3.34

MiNK Therapeutics Inc Stock (INKT) Company Profile

Name

MiNK Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

212 994 8250

Address

149 Fifth Avenue, Suite 500, New York

Employee

Twitter

Next Earnings Date

2024-06-12

Latest SEC Filings

INKT's Discussions on Twitter

MiNK Therapeutics Inc Stock (INKT) Latest News

William Blair Analysts Boost Earnings Estimates for MiNK Therapeutics, Inc. (NASDAQ:INKT) - Defense World

Defense World

Are Smart Investors Making the Right Decision? MiNK Therapeutics Inc (INKT) – Sete News - SETE News

SETE News

MiNK Therapeutics' (INKT) Buy Rating Reiterated at HC Wainwright - Defense World

Defense World

MiNK Therapeutics Inc (INKT) is an excellent investment, but the stock is overvalued/undervalued right now – US Post ... - US Post News

US Post News

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

MiNK Reports First Quarter 2024 Results | National | wdrb.com - WDRB

WDRB

MiNK Therapeutics Inc Stock (INKT) Financials Data

MiNK Therapeutics Inc (INKT) Net Income 2024

INKT net income (TTM) was -$24.77 million for the quarter ending September 30, 2023, a +4.68% increase year-over-year.

MiNK Therapeutics Inc (INKT) Cash Flow 2024

INKT recorded a free cash flow (TTM) of -$17.36 million for the quarter ending September 30, 2023, a -6.75% decrease year-over-year.

MiNK Therapeutics Inc (INKT) Earnings per Share 2024

INKT earnings per share (TTM) was -$0.73 for the quarter ending September 30, 2023, a +5.46% growth year-over-year.

MiNK Therapeutics Inc Stock (INKT) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
AGENUS INC	10% Owner	Oct 13 '23	Buy	1.10	19,373	21,310	21,772,434
AGENUS INC	10% Owner	Oct 12 '23	Buy	1.10	3,173	3,488	21,753,061
AGENUS INC	10% Owner	Oct 04 '23	Buy	1.09	15,001	16,380	21,749,888
AGENUS INC	10% Owner	Aug 29 '23	Buy	1.52	29,678	45,016	21,734,887
AGENUS INC	10% Owner	Aug 28 '23	Buy	1.45	12,808	18,570	21,705,209
AGENUS INC	10% Owner	Aug 24 '23	Buy	1.54	170,244	262,908	21,692,401

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.